Stock Analysis on Net

Amgen Inc. (NASDAQ:AMGN)

Cash Flow Statement

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Amgen Inc., consolidated cash flow statement

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Net income 4,090 6,717 6,552 5,893 7,264
Depreciation, amortization and other 5,592 4,071 3,417 3,398 3,601
Stock-based compensation expense 530 431 401 341 330
Deferred income taxes (1,228) (1,273) (1,198) (453) (287)
Acquired in-process research and development 1,505
Adjustments for equity method investments (10) 11 891 33 65
Loss on divestiture 567
(Gains) losses on equity securities 159 (1,565) 127
Other items, net (8) 563 (303) (262) (260)
Noncash adjustments to reconcile net income to net cash provided by operating activities 5,035 2,238 3,902 4,562 3,449
Trade receivables, net 441 (1,015) (746) (429) (427)
Inventories 2,532 491 (742) (165) (215)
Other assets (652) (564) 258 (237) 129
Accounts payable 312 (402) 154 (69) 45
Accrued income taxes, net (1,011) (1,031) (647) (854) (249)
Long-term tax liabilities (492) 371 229 204 (482)
Accrued liabilities 92 953 97
Accrued sales incentives and allowance 1,194 935 846 404
Other liabilities (51) (222) (182) (48) 983
Changes in operating assets and liabilities, net of acquisitions 2,365 (484) (733) (1,194) (216)
Net cash provided by operating activities 11,490 8,471 9,721 9,261 10,497
Cash paid for acquisitions, net of cash acquired (26,989) (3,839) (2,529)
Purchases of marketable securities (1) (2,587) (8,900) (8,477)
Proceeds from sales of marketable securities 1,123 98 4,403 2,597
Proceeds from maturities of marketable securities 550 1,120 8,831 4,381
Purchases of property, plant and equipment (1,096) (1,112) (936) (880) (608)
Other 50 225 100 (192) (3,294)
Net cash (used in) provided by investing activities (1,046) (26,204) (6,044) 733 (5,401)
Net proceeds from issuance of debt 27,777 6,919 4,945 8,914
Extinguishment of debt (659) (647) (297)
Repayment of debt (3,600) (1,454) (4,150) (6,450)
Repurchases of common stock (200) (6,360) (4,975) (3,486)
Dividends paid (4,832) (4,556) (4,196) (4,013) (3,755)
Other (124) (72) (103) (78) (90)
Net cash provided by (used in) financing activities (9,415) 21,048 (4,037) (8,271) (4,867)
Increase (decrease) in cash and cash equivalents 1,029 3,315 (360) 1,723 229
Cash and cash equivalents at beginning of year 10,944 7,629 7,989 6,266 6,037
Cash and cash equivalents at end of year 11,973 10,944 7,629 7,989 6,266

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Cash flow statement item Description The company
Net cash provided by operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Amgen Inc. net cash provided by operating activities decreased from 2022 to 2023 but then increased from 2023 to 2024 exceeding 2022 level.
Net cash (used in) provided by investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Amgen Inc. net cash (used in) provided by investing activities decreased from 2022 to 2023 but then increased from 2023 to 2024 exceeding 2022 level.
Net cash provided by (used in) financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Amgen Inc. net cash provided by (used in) financing activities increased from 2022 to 2023 but then decreased significantly from 2023 to 2024.